secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2022-03-24T23:59:59+00:00
Accession:  0001785530-22-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports 2021 net loss $50M, cash $157.5M; IND filings on track
--------------------------------------------------------------------------------

- Net loss $17.9M in Q4 2021 ($7.4M Q4 2020); full-year loss $50.0M ($15.0M 2020).
- Cash $157.5M at Dec 31, 2021 ($92.6M Dec 31, 2020); runway through at least Q2 2023.
- R&D expenses $35.3M in 2021 ($16.6M 2020); G&A $14.8M ($5.8M).
- IND for WTX-124 expected Q2 2022; IND for WTX-330 early Q3 2022.
- Announced clinical trial collaboration with Merck for WTX-124 + Keytruda in solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000012/0001785530-22-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553022000012/howl-20220324.htm
  HTML page:      https://secwatch.observer/filing/0001785530-22-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer